Core Viewpoint - Zhonghui Biotech-B (02627) has achieved a significant milestone with the approval of the first and only trivalent subunit influenza vaccine for the entire population in China, enhancing its product matrix in the subunit influenza vaccine sector [1][4]. Group 1: Product Development and Market Position - The company’s quadrivalent subunit influenza vaccine (Hui Er Kang Xin®) was the first to achieve full population coverage in China, establishing a strong foundation for the newly approved trivalent vaccine [4]. - The successful approval of the trivalent vaccine allows the company to better meet diverse public health needs and market preferences, potentially driving sustained performance and value reassessment [4][8]. - The global influenza activity has been increasing, with a significant gap in vaccination rates in China compared to international levels, indicating a long-term structural growth opportunity for the company [5]. Group 2: Commercialization and Financial Performance - The quadrivalent vaccine has demonstrated strong commercial viability, with revenue projected to grow from 52.168 million yuan in 2023 to 260 million yuan in 2024, and a staggering 918.91% year-on-year growth in the first half of 2025 [7]. - The vaccine has maintained a 100% approval rate for product batch issuance since its launch, expanding its sales network across over 1,100 disease control centers in 30 provinces [7]. - The company has made progress in market access, with the quadrivalent vaccine passing preliminary review for inclusion in the 2025 National Commercial Health Insurance innovative drug list, which may alleviate market promotion pressures [7]. Group 3: Future Growth and R&D Pipeline - The company is actively expanding its product offerings, including a clinical trial for an adjuvanted vaccine targeting individuals aged 65 and older, and research for a vaccine specifically for pregnant women [8][10]. - The company has a robust pipeline with multiple promising products, including a freeze-dried rabies vaccine currently in phase III clinical trials, which is expected to become a significant growth driver alongside the influenza vaccines [10]. - The company is also pursuing international markets, with plans to expand into Canada, Singapore, Mexico, and Hong Kong by 2026, enhancing its global competitiveness [11]. Group 4: Market Outlook and Analyst Ratings - Analysts predict that the company will achieve profitability by 2027, with projected revenues of 798 million yuan and 1.24 billion yuan for 2026 and 2027, respectively, indicating a clear growth trajectory [11]. - The successful approval of the trivalent influenza vaccine is expected to provide immediate revenue growth and strengthen the company's competitive advantage in the high-potential subunit vaccine sector [11].